Drug combo for advanced stomach cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced or metastatic stomach cancer that has grown after one previous treatment.
- Your tumor has a marker called PD-L1 (a protein that may help the cancer avoid your immune system).
- You have at least one tumor that can be measured on imaging tests.
- You are in reasonably good health (able to do light activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.